Gilead official announced that the price of Redcivir is only 10% of the lowest price of 390 US dollars/bottle of generic drugs!

Gilead Sciencerecent recently announced a price tag for remdesivir at $390 a bottle, and most patients are expected to receive a five-day course of treatment for a total of six bottles at a price of $2,340Investors at least did not seem to be shocked, with Gilead's shares up about 2 percent in early tradingBy helping patients get out of hospital quickly, MrRedsewey should be able to immediately save the health care system a net cost, MrGield saidSo far, the only strong Phase III study, ACTT data, shows that Redseywe reduced recovery time by four days compared to placebos (11 days vs 15 days, p 0.001);but the price has drawn criticism from many quartersThe phase III, which was run by the National Institute of Allergy and Infectious Diseases (NIAID), is actually paid for by American taxpayers, some of which believe they should get a lower priceOthers worry that Redsewe has not yet been shown to reduce the risk of deathearly May, the American Institute for Clinical and Economic Review (ICER) measured Redseweh's pricing and concluded that the $10 price for every 10-day course of treatment would cover production costs, regardless of investment in research and development, and that a $4,500 price would be considered cost-effective if the benefits of death were clarifiedRelated Read: Redside Commercialization In, Gilead Wins Geometry?, ICER recently launched a new analysis that found Redsewe's $2,500-$2,800 price to be cost-effective, slightly higher than Gilead's ownHowever, the ICER analysis assumes two very important factors: the inclusion of the steroid drug dexamethasone as a standard care, and the other is that Redsewe shows the benefits of deaththe first factor seems likely to happen, with one study finding that the cheap steroid could reduce the death rate of patients with COVID-19 severe ventilation by a thirdThe second factor, however, is far from assuredIn the ACTT study, NIAID found that the Redsewe group had lower mortality rates on the 14th day than the placebo group (8% vs 12%), but the difference sharply did not show significant;ICER concluded that if the benefits of death were not shown, Redsewe's cost-effectiveness benchmark would have fallen to $310 If the positive signs of this survival benefit are not consistent in Redsewe's clinical studies, Gilead may find it harder to get rid of criticism of its pricing Despite this, seller analysts now have a price to simulate future sales The chart above, from EvaluatePharma, shows the current seller consensus, which includes some very different numbers This partly reflects differing perceptions of redssewer's demand and price, which were also pre-edifying the study of CAVID-19 in Dexametason SVB Leerink's report noted that Gilead's pricing for Redsewey fell short of its expectations, although analysts still expected Gilead to make a profit from Redsewe Analysts at SunTrust Robinson are skeptical that, with Redsewe's investment spending of $1bn this year alone, how can Gilead recover its investment in the short term? Gilead and its investors also want to recover costs as soon as possible With progress still unknown about the progress of the COVID-19 pandemic and other potential therapies, this means that Redsewe's pricing needs to be as high as possible it's worth noting that on the 20th of this month, two Redsiwel generics were approved for sale in India, from Cipremi and Covifor, which are priced at $39-$52 each and $65-$78 each Under current guidelines from the Indian government, a case of COVID-19 patients may require 5-6 doses of medication, which means that the total cost of the entire course of antiviral therapy in Redsivir could be as low as $195 .